Dilutional therapy with tolvaptan favourably alters cystine saturation in the urine and increases urine output in patients with cystinuria, as shown in a small study, suggesting the drug’s potential in reducing the recurrence of stones in this population.
Delays in radical prostatectomy due to the novel coronavirus disease (COVID-19) pandemic does not result in adverse pathology, upgrading, nodal metastasis, or use of postsurgery secondary treatments, according to a recent study.
Tobacco smoking exposure appears to result in lower neoadjuvant chemotherapy response rates as well as higher overall and cancer-specific mortality, according to a systematic review and meta-analysis. Smoking status is also associated with bladder cancer recurrence after radical cystectomy.
The placement of an absorbable perirectal hydrogel spacer (HS) led to prostate-rectum separation with less rectal irradiation, fewer rectal toxicities, and better bowel-related quality of life (QoL) in men undergoing radiotherapy (RT) for prostate cancer (PCa), a meta-analysis has shown.
A novel hand-powered spinning device, which employs the principles of centrifugal force and a fidget spinner toy, can perform on-site detection of urinary tract infection (UTI) in about 50 minutes and may prove useful in low-resource settings, as reported in a study.
Treatment with vibegron 75 mg once daily effectively lowers micturitions, urgency episodes, and urge incontinence and increases the volume per micturition in patients with symptoms of overactive bladder (OAB), results of an international phase III study have shown. It is also safe and well tolerated.
Sacral neuromodulation (SNM) was not as cost-effective as serial intradetrusor injections of onabotulinumtoxinA (BTX) for the treatment of refractory urgency urinary incontinence (UUI), the ROSETTA* trial has shown.
The addition of enzalutamide to androgen deprivation therapy (ADT) improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), demonstrated the phase III PROSPER* trial.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.